Free Trial

Trevi Therapeutics Q2 2023 Earnings Report

Trevi Therapeutics logo
$6.50 -0.03 (-0.46%)
As of 03/28/2025 04:00 PM Eastern

Trevi Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Trevi Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Trevi Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Trevi Therapeutics Earnings Headlines

B. Riley Predicts Weaker Earnings for Trevi Therapeutics
Why Buffett and 100 members of Congress are Piling into this One Investment
While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.
Leerink Partnrs Issues Optimistic Outlook for TRVI Earnings
Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst
See More Trevi Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trevi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevi Therapeutics and other key companies, straight to your email.

About Trevi Therapeutics

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

View Trevi Therapeutics Profile

More Earnings Resources from MarketBeat